Case report shows successful alternative sonidegib administration in a patient with Gorlin-Goltz syndrome and dysphagia, indicating improved treatment access.
Activation of the Hedgehog pathway is a key factor in the development of basal cell carcinoma. Approved Hedgehog pathway inhibitors, like vismodegib and sonidegib, are supplied in capsule form. Patients who suffer from dysphagia may have problems swallowing these medications. This case report describes the successful use of an alternative administration of sonidegib in a patient with Gorlin-Goltz syndrome and dysphagia.
No takes yet. Share an insight, caveat, or question.
Bender et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: